Abstract
Novel therapeutic strategies using nucleic acid drugs, such as plasmid DNA (pDNA) and nuclear factor-κB (NFκB) decoy, have been sought for non-treatable neurological disorders. Among them, the application of pDNA has been extensively studied in diabetic neuropathy. Since growth factors, such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), have both neurotrophic and angiogenic properties, intramuscular injection of pDNA encoding these genes has been examined and shown to be effective for treatment in experimental animals and also in clinical trials. These growth factors have also been shown to accelerate neuroprotection, angiogenesis, and regeneration in the brain, and overexpression of these factors showed therapeutic effects in cerebral ischemia in rodents. Inhibition of inflammation is another strategy to treat cerebrovascular diseases. Recent studies suggest that NFκB plays critical roles in the formation of cerebral aneurysms, and inhibition of its function by NFκB decoy was shown to prevent cerebral aneurysm enlargement through inhibition of NFκB-mediated inflammation. In the field of neurodegenerative disease, the potential of pDNA as a tool for vaccination has attracted researchers since pDNA itself has shown adjuvant properties and the potential to induce immunity or immune tolerance. pDNA encoding disease antigens, such as amyloid-Aβ in Alzheimer disease or myelin basic protein in multiple sclerosis (MS), was shown to have therapeutic effects in rodents, and its efficacy and safety were reported in a phase I/II clinical study in MS. In this review, we discuss the potential and problems of nucleic acid drugs in neurological disorders.
Keywords: Nucleic acid drug, plasmid DNA, NFκB decoy, diabetic neuropathy, cerebral ischemia, Alzheimer disease, multiple sclerosis, DNA vaccine, non-treatable neurological disorders, diabetic neuropathy, inflammation, multiple sclerosis (MS)
Current Topics in Medicinal Chemistry
Title:Development of Nucleic Acid Drugs for Neurological Disorders
Volume: 12 Issue: 15
Author(s): Munehisa Shimamura, Naoyuki Sato, Hironori Nakagami, Yoshiaki Taniyama and Ryuichi Morishita
Affiliation:
Keywords: Nucleic acid drug, plasmid DNA, NFκB decoy, diabetic neuropathy, cerebral ischemia, Alzheimer disease, multiple sclerosis, DNA vaccine, non-treatable neurological disorders, diabetic neuropathy, inflammation, multiple sclerosis (MS)
Abstract: Novel therapeutic strategies using nucleic acid drugs, such as plasmid DNA (pDNA) and nuclear factor-κB (NFκB) decoy, have been sought for non-treatable neurological disorders. Among them, the application of pDNA has been extensively studied in diabetic neuropathy. Since growth factors, such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), have both neurotrophic and angiogenic properties, intramuscular injection of pDNA encoding these genes has been examined and shown to be effective for treatment in experimental animals and also in clinical trials. These growth factors have also been shown to accelerate neuroprotection, angiogenesis, and regeneration in the brain, and overexpression of these factors showed therapeutic effects in cerebral ischemia in rodents. Inhibition of inflammation is another strategy to treat cerebrovascular diseases. Recent studies suggest that NFκB plays critical roles in the formation of cerebral aneurysms, and inhibition of its function by NFκB decoy was shown to prevent cerebral aneurysm enlargement through inhibition of NFκB-mediated inflammation. In the field of neurodegenerative disease, the potential of pDNA as a tool for vaccination has attracted researchers since pDNA itself has shown adjuvant properties and the potential to induce immunity or immune tolerance. pDNA encoding disease antigens, such as amyloid-Aβ in Alzheimer disease or myelin basic protein in multiple sclerosis (MS), was shown to have therapeutic effects in rodents, and its efficacy and safety were reported in a phase I/II clinical study in MS. In this review, we discuss the potential and problems of nucleic acid drugs in neurological disorders.
Export Options
About this article
Cite this article as:
Shimamura Munehisa, Sato Naoyuki, Nakagami Hironori, Taniyama Yoshiaki and Morishita Ryuichi, Development of Nucleic Acid Drugs for Neurological Disorders, Current Topics in Medicinal Chemistry 2012; 12 (15) . https://dx.doi.org/10.2174/156802612803531405
DOI https://dx.doi.org/10.2174/156802612803531405 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alogliptin; A Review of a New Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Cardiovascular & Hematological Disorders-Drug Targets CDKN2B-AS1: An Indispensable Long Non-coding RNA in Multiple Diseases
Current Pharmaceutical Design MEFV Mutation Carriers and Diseases Other than Familial Mediterranean Fever: Proved and Non-Proved Associations; Putative Biological Advantage
Current Drug Targets - Inflammation & Allergy Editorial [ Cardiovascular Risk Factor Modification: A sine qua non in the Management of Vascular Surgery Patients ]
Current Vascular Pharmacology Serum Biochemical Markers of Brain Injury
Mini-Reviews in Medicinal Chemistry A Cyclooxygenase-2 Inhibitor Reduces Vascular Wall Thickness and Ameliorates Cognitive Impairment in a Cerebral Small Vessel Diseases Rat Model
Current Alzheimer Research Molecular, Cellular and Clinical Aspects of Intracerebral Hemorrhage: Are the Enemies Within?
Current Neuropharmacology Should We be Concerned About the Inflammatory Response to Endovascular Procedures?
Current Vascular Pharmacology The Brain, the Penis and Steroid Hormones: Clinical Correlates with Endothelial Dysfunction
Current Pharmaceutical Design State of the Art Management of Transfusion-Related Acute Lung Injury (TRALI)
Current Pharmaceutical Design A Survey on Synthesis Processes of Structured Materials for Biomedical Applications: Iron-based Magnetic Nanoparticles, Polymeric Materials and Polymerization Processes
Current Pharmaceutical Design Cholesterol Lowering Therapy: Treat to Target or Reduce the Global Risk? The Unresolved Problem of Residual Risk
Current Pharmaceutical Design Pharmacotherapy of Abdominal Aortic Aneurysms
Current Vascular Pharmacology Hemolytic Uremic Syndrome in Children
Current Pediatric Reviews Q Fever Endocarditis
Infectious Disorders - Drug Targets The Appearance of Middle Meningeal Artery Fistulae After Willis Covered Stent for Traumatic Carotid-cavernous Fistulae: Two Case Reports
Current Medical Imaging Experimental Models of Abdominal Aortic Aneurysms: An Overview
Current Pharmaceutical Design From Diabetes to Metabolic Syndrome: A View Point on An Evolving Concept
Current Pharmaceutical Design Cellular and Molecular Effects of Macrolides on Leukocyte Function
Current Pharmaceutical Design Prevalence of Neutralizing Factors Against Adeno-Associated Virus Types 2 in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
Current Gene Therapy